Clinical Trial Roster Shows Breadth of Ongoing Research

Lee M. Krug, MD
Published: Thursday, Aug 07, 2014
Memorial Sloan-Kettering Cancer CenterLee M. Krug, MD
Lee M. Krug, MD
Thoracic Oncologist
Director, Mesothelioma Program
Memorial Sloan Kettering Cancer Center
New York, NY Strategic Partnership
At Memorial Sloan Kettering, we offer a variety of clinical trials for patients with mesothelioma at all stages of their disease. These trials focus on a range of topics, from looking for genetic factors that predispose people to mesothelioma to exploring ways to combine chemotherapy, surgery, and radiation to optimize outcomes. We also have studies investigating novel therapeutic options.

Genetic Studies

Our researchers are actively working to identify the factors that predispose people to developing mesothelioma. We have found mutations in BRCA1–associated protein (BAP1) in approximately 20% of mesothelioma tumors.1 There are also rare familial cases of mesothelioma related to germline BAP1 mutations.

Patients with mesothelioma can take advantage of our clinical studies (protocols 12-235 and 12-245) that analyze tumor and blood specimens for BAP1 and other mutations. Further investigation of these mutations may reveal clues about the causes of mesothelioma and will hopefully lead to the development of improved treatments.

Surgery and Early-Stage Disease

Some patients with pleural mesothelioma are candidates for surgery, which most often involves resection of the lining of the lung (pleurectomy/ decortication). However, surgery alone is not adequate, and other treatments, such as chemotherapy and radiation, are required to decrease the risk of recurrence. Our radiation oncologists have developed an innovative technique of administering intensity-modulated radiation therapy (IMRT) to the entire pleura while sparing the lung.2

A trial involving chemotherapy, pleurectomy, and pleural radiation (protocol 08-053) has just completed enrollment, and we are now analyzing the data. Soon, we plan to conduct a large, multicenter study of pleurectomy followed by chemotherapy, with or without pleural IMRT.

For other patients with early-stage disease, we are exploring a unique approach that involves intrapleural administration of an oncolytic virus (protocol 12-169). This vaccinia virus has been modified so that it is not pathogenic but does infect and kill cancer cells. The aim of this trial is to demonstrate the safety of the approach; to date, no serious treatment-related toxicities have occurred. In another study, we are investigating whether a particular vaccine can delay or prevent recurrence of mesothelioma after surgery (protocol 10-134). The vaccine was developed by Memorial Sloan Kettering researchers to immunize against WT1, a protein that regulates gene expression and cell growth and is commonly overexpressed in mesothelioma.3

Systemic Treatments

Patients with mesothelioma not amenable to surgery are typically treated with chemotherapy (pemetrexed with cisplatin or carboplatin). For such patients, we are adding LY3023414, a small molecule administered in an oral capsule, to the chemotherapy regimen to determine the safety and efficacy of this combination. LY3023414 blocks growth signals in cancer cells, and a similar drug has already been shown to shrink tumors in patients with mesothelioma. Another group of patients will receive LY3023414 alone. This trial (protocol 12-286) will open enrollment in August 2014.

In protocol 13-185, we aim to identify a treatment that maintains a response to chemotherapy. The drug being tested is defactinib (otherwise known as VS-6063), which acts by inhibiting focal adhesion kinase, a molecule involved in cell structure and migration. In preclinical models, defactinib is most effective in NF2-mutant tumors. NF2 is aberrant in up to 70% of mesotheliomas. In this study, patients with a minimum of stable disease after four cycles of chemotherapy are randomly assigned to receive either defactinib or placebo.

Finally, we are participating in a randomized trial of tremelimumab versus placebo for patients with progression after first-line chemotherapy (protocol 13-092). Tremelimumab is a monoclonal antibody that blocks CTLA-4 (similar to ipilimumab) and has shown activity in patients with mesothelioma.

DESCRIPTION
References
  1. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668-672.
  2. Rosenzweig KE, Zauderer MG, Laser B, et al. Pleural intensitymodulated radiotherapy for malignant pleural mesothelioma [published online May 18, 2012]. Int J Radiat Oncol Biol Phys. 2012;83(4):1278-1283.
  3. Krug LM, Dao T, Brown AB, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer [published online June 8, 2010]. Cancer Immunol Immunother. 2010;59:1467-1479.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x